Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / India News / Bharat Biotech allowed COVAXIN trials on children aged 12+
    Next Article
    Bharat Biotech allowed COVAXIN trials on children aged 12+

    Bharat Biotech allowed COVAXIN trials on children aged 12+

    By Siddhant Pandey
    Jan 04, 2021
    06:56 pm

    What's the story

    Hyderabad-based pharmaceutical company Bharat Biotech has been allowed to conduct clinical trials for its COVID-19 vaccine on children above the age of 12.

    On Sunday, the firm's vaccine, called COVAXIN, had been granted emergency approval for use, albeit in "clinical trial mode" only.

    The vaccine has been undergoing Phase III trials and its efficacy is yet to be ascertained.

    Here are more details.

    Vaccination

    Yesterday, government had approved two vaccines

    On Sunday, the government had approved two vaccines: COVAXIN and Covishield (developed by AstraZeneca and Oxford University, and manufactured by Pune-based Serum Institute of India).

    So far, the government has said the vaccination drive will only focus on adults.

    However, COVAXIN has been approved in "clinical trial mode," i.e., its recipients would be tracked and monitored as if they were in a clinical trial.

    You're
    20%
    through

    Information

    COVAXIN already administered to children in last round of trials

    Notably, COVAXIN has already been given to children above the age of 12 in the last round of trials. It has been found "safe" so far. Phase I and II trials also showed that the vaccine had a "robust immune response."

    You're
    40%
    through

    Controversy

    Questions raised over vaccine's efficacy with trial still underway

    The approval for restricted use for COVAXIN has invited controversy as the company is yet to complete clinical trials and submit data on efficacy.

    The Opposition has demanded that the vaccine's use should be avoided until the trials have concluded.

    Meanwhile, Health Minister Dr. Harsh Vardhan has said that the Opposition was politicizing a "critical issue," adding that "science-backed protocols" were followed for approval.

    You're
    60%
    through

    Advantage

    COVAXIN more effective against mutated virus: ICMR chief

    COVAXIN is an inactivated vaccine, i.e., it uses an inactivated or killed pathogen (SARS-CoV-2) to trigger an immune response.

    Indian Council of Medical Research (ICMR) Director-General Dr. Balram Bhargava told The Print that the vaccine is more likely to act against the new mutant strain of the coronavirus as it uses the whole virus.

    The ICMR has jointly developed COVAXIN with Bharat Biotech.

    You're
    80%
    through

    Quote

    'mRNA vaccines may not work as well against mutated virus'

    Dr. Bhargava said, "If there are say 1,000 points in a vaccine, of which two have mutated, this is still going to have 998 points to generate a response, unlike others such as mRNA vaccines, which...may not work as well when those areas mutate."

    Done!
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Oxford University
    Coronavirus
    Serum Institute of India
    Bharat Biotech

    Latest

    Parvez Hossain Emon becomes Bangladesh's second T20I centurion: His stats Bangladesh Cricket Team
    Pakistan announces global outreach against 'Operation Sindoor,' Bilawal to lead Islamabad
    Mani Ratnam-Naveen Polishetty uniting for a love story? Find out Mani Ratnam
    Ukraine reports largest Russian drone attack since 2022 Donald Trump

    Oxford University

    New COVID-19 vaccine goes into human trials: Details here Vaccine
    COVID-19 vaccine: What are the latest updates? Oxford
    Oxford's COVID-19 vaccine: All you need to know COVID-19 Vaccine
    #GoodNews: Oxford's COVID-19 vaccine may be available by September-end Oxford

    Coronavirus

    Karnataka hints at police action against untraceable UK returnees Karnataka
    Coronavirus: India reports 16K+ new cases, lowest spike since June India
    New coronavirus strain reaches India; six UK returnees test positive United Kingdom
    More COVID-19 vaccines in pipeline as US ramps up effort Donald Trump

    Serum Institute of India

    Serum Institute gets notice after AstraZeneca halts coronavirus vaccine trial University of Oxford
    Big setback: Serum pauses Oxford's coronavirus vaccine trial in India Oxford
    Coronavirus: Serum Institute ordered to halt recruitment for vaccine trial Vaccine
    Coronavirus vaccine won't be available for all before 2024-end: Poonawalla Independence Day

    Bharat Biotech

    ICMR, Bharat Biotech teaming up to develop Indian COVID-19 vaccine Indian Council of Medical Research (ICMR)
    India's first COVID-19 vaccine, COVAXIN, cleared for human trials Coronavirus
    India targets to launch first COVID-19 vaccine by August 15 Indian Council of Medical Research (ICMR)
    India's second COVID-19 vaccine cleared for human trials: Details here Drugs Controller General of India
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025